The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response of HER2+ breast cancer patients to allogeneic cell immunotherapy.
Michael Har-Noy
Employment or Leadership Position - Immunovative Therapies (U)
Stock Ownership - Immunovative Therapies
Wirote Lausoontornsiri
No relevant relationships to disclose
Reuven Or
No relevant relationships to disclose
Emmanual Katsanis
Research Funding - Immunovative Therapies